A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy

Journal of Infectious Diseases

Volumn 192, Issue 8, 2005, Pages 1398-1406

  Collier, Ann C ^a,g   Ribaudo, Heather ^b   Mukherjee, A Lisa ^b   Feinberg, Judith ^c   Fischl, Margaret A ^d   Chesney, Margaret ^e,f  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; AGE; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION ANTIRETROVIRAL THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERPERSONAL COMMUNICATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT COUNSELING; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; SEX DIFFERENCE; SOCIAL SUPPORT; SUPPORT GROUP; TECHNIQUE; TELEPHONE; TREATMENT FAILURE; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 25844435301     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/466526     Document Type: Article

References (54)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-33.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
3. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study: Swiss HIV Cohort Study. Lancet 1999; 353:863-8.
4. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
5. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003; 17:1741-51.
6. Paterson DL, Swindells SL, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
7. Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther 2002; 7:185-93.
8. Garcia de Ollalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30:105-10.
9. Chesney M. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30(Suppl 2):S171-6.
10. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002; 31(Suppl 3):S123-7.
11. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2001; 26:82-92.
12. Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDs 1999; 13:185-97.
13. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996; 8:261-9.
14. Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002; 16:2175-82.
15. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002; 17:756-65.
16. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000; 23:386-95.
17. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001; 28:232-9.
18. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med 2003; 11:185-98.
19. Lyon ME, Trexler C, Akpan-Townsend C, et al. A family group approach to increasing adherence in HIV-infected youths: results of a pilot project. AIDS Patient Care STDs 2003; 17:299-308.
20. Smith SR, Rublein JC, Marcus C, Brock TP, Chesney MA. A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns 2003; 50:187-99.
21. Dilorio C, Resnicow K, McDonnell M, Soet J, McCarty F, Yeager K. Using motivational interviewing to promote adherence to antiretroviral medications: a pilot study. J Assoc Nurses AIDS Care 2003; 14:52-62.
22. Molassiotis A, Lopez-Nahas V, Chung WY, Lam SW. A pilot study of the effects of a behavioural intervention on treatment adherence in HIV-infected patients. AIDS Care 2003; 15:125-35.
23. Broadhead RS, Heckathorn DD, Altice FL, et al. Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Soc Sci Med 2002; 55:235-46.
24. Saften SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther 2001;39:1151-62.
25. Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med 2000; 15:841-7.
26. Holzemer WL, Henry SB, Portillo CJ, Miramontes H. The Client Adherence Profiling-Intervention Tailoring (CAP-IT) intervention for enhancing adherence to HIV/AIDS medications: a pilot study. J Assoc Nurses AIDS Care 2000; 11:36-44.
27. Wall TL, Sorensen JL, Batki SL, Delucchi KL, London JA, Chesney MA. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend 1995; 37:261-9.
28. Weber R, Christen L, Christen S, et al. Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial. Antivir Ther 2004; 9:85-95.
29. Knobel H, Carmona A, Lopez JL, et al. Adherence to very active antiretroviral treatment: impact of individualized assessment. Enferm Infecc Microbiol Clin 1999; 17:78-81.
30. Pradier C, Bentz L, Spire B, et al. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials 2003; 4:21-31.
31. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25:221-8.
32. Fischl MA, Ribaudo HJ, Collier AC, et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003; 188:625-34.
33. Riddler SA, Havlir D, Squires KE, et al. Coadministration of indinavir and nelfinavir human immunodeficiency virus type-1-infected adults: safety, pharmacokinetics, and antiretroviral activity. Antimicrob Agents Chemother 2002; 46:3877-82.
34. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12:255-66.
35. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measurement 1997; 1:385-401.
36. Liang K-Y, Zeger SL. Longitudinal data analyses using generalized linear models. Biometrika 1986; 73:13-22.
37. Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 2002; 346:1373-82.
38. Cunningham WE, Bozzette SA, Hays RD, Kanouse DE, Shapiro MF. Comparison of health-related quality of life in clinical trial and nonclinical trial human immunodeficiency virus-infected cohorts. Med Care 1995; 33(4 Suppl):AS15-25.
39. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999; 29:824-30.
40. Catz SL, Kelly JA, Bogart LM, Bentosch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000; 19:124-33.
41. Nieuwkerk P, Gisolf E, Sprangers M, Danner S. Adherence of 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response. Antivir Ther 2001; 6:97-103.
42. Frick PA, Gal P, Lane TW, Sewell PC. Antiretroviral medication compliance in patients with AIDS. AIDS Patient Care STDs 1998; 12:463-70.
43. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33: 1417-23.
44. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDs 2002; 16:599-608.
45. Duong M, Piroth L, Grappin M, et al. Evaluation of the patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens. HIV Clin Trials 2001; 2:128-35.
46. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999; 13:1099-107.
47. Wagner GJ, Ghosh-Dastidar B. Electronic monitoring: adherence assessment or intervention? HIV Clin Trials 2002; 3:45-51.
48. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:435-42.
49. Mathews WC, Mar-Tang M, Ballard C, et al. Prevalence, predictors, and outcomes of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care STDs 2002; 16:157-72.
50. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseu F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15:1369-77.
51. van Servellen G, Chang B, Garcia L, Lombardi E. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDs 2002; 16:269-81.
52. Kalichman SC, Rompa D, DiFonzo K, et al. HIV treatment adherence in women living with HIV/AIDS: research based on the Information-Motivation-Behavioral Skills model of health behavior. J Assoc Nurses AIDS Care 2001; 12:58-67.
53. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M, Adolescent Medicine HIV/AIDS Research Network. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2001; 13:27-40.
54. Saften SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther 2001; 39:1151-62.